Citation Impact
Citing Papers
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
2009
Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways
2016
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
2016
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
2016
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
2010 Standout
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Activation of Akt-1 (PKB-α) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion
2004
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
2010
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
2012
Hallmarks of Cancer: The Next Generation
2011 Standout
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients
2005
Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma
2006
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
2011
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
2014
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
2010
EGFR Antagonists in Cancer Treatment
2008 Standout
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
2011
Molecular imaging in drug development
2008 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Advances and challenges in targeting FGFR signalling in cancer
2017
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
2011 StandoutNobel
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
PI3K pathway alterations in cancer: variations on a theme
2008
Should individual PI3 kinase isoforms be targeted in cancer?
2009
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
2005
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
2013
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
2009
The molecular biology of head and neck cancer
2010 Standout
PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality
2009
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
2011
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
2013
Metazoan MicroRNAs
2018 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Perturbations of the AKT signaling pathway in human cancer
2005
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Increased activated Akt expression in renal cell carcinomas and prognosis
2008
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Portrait of PTEN: Messages from mutant mice
2008 StandoutNobel
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
2012 Standout
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Akt signalling in health and disease
2011 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
2010
The PI3K Pathway in Human Disease
2017 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer
2007
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Akt Blocks Breast Cancer Cell Motility and Invasion through the Transcription Factor NFAT
2005
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Apoptosome dysfunction in human cancer
2004
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
The Fibroblast Growth Factor signaling pathway
2015 Standout
Development of Organometallic S6K1 Inhibitors
2014
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
2010
The Pharmacology of mTOR Inhibition
2009 Standout
Fundamentals of cancer metabolism
2016 Standout
Akt-Mediated Phosphorylation and Activation of Estrogen Receptor α Is Required for Endometrial Neoplastic Transformation in Pten+/− Mice
2006
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer
2016
Context-Specific Function of S6K2 in Th Cell Differentiation
2016
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
2010
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes
2011
Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease
2005
Cancer Genome Landscapes
2013 StandoutScience
Drug Resistance in Cancer: An Overview
2014 Standout
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
The ins and outs of fibroblast growth factor receptor signalling
2014
Works of Birgit Olsson being referenced
Amplification of HSD17B1 and ERBB2 in primary breast cancer
2003
Akt kinases in breast cancer and the results of adjuvant therapy
2003
Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
2010
High‐resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1
2011
Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
2000
PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer
2007